GLP-1 receptor agonists, the same drugs used for weight loss and diabetes, are emerging as potential treatments for chronic pain and addiction, though evidence remains preliminary and risks require careful monitoring. While early data is encouraging, particularly for knee osteoarthritis and alcohol use disorder, researchers emphasize that these medications are not a cure-all and require rigorous clinical trials before widespread use in pain and addiction care .

What Evidence Exists for GLP-1 Drugs and Chronic Pain?

The strongest evidence for pain relief comes from knee osteoarthritis. In a 68-week placebo-controlled trial, once-weekly semaglutide injections (brand names Ozempic and Wegovy) in people with obesity and moderate knee osteoarthritis produced significantly greater reductions in body weight, along with significant improvements in pain scores and better physical function . However, researchers are still determining how much of the pain relief comes directly from weight loss versus metabolic improvements that reduce inflammation.

Outside of osteoarthritis, the evidence is thinner but intriguing. Preclinical studies suggest GLP-1 receptor agonists may reduce neuropathic pain, which is pain caused by nerve damage, through anti-inflammatory and neuroprotective effects. A particularly promising real-world signal comes from fibromyalgia. A large analysis of over 96,000 patients found that GLP-1 use was associated with significantly lower odds of needing an opioid prescription or of being diagnosed with chronic pain and fatigue . These observational data are hypothesis-generating, but require confirmation in future studies.

Can GLP-1 Drugs Help With Addiction?

The evidence for addiction treatment is surprisingly strong, though still preliminary. GLP-1 drugs appear to modulate reward pathways in the brain that shape craving and compulsive drug use. A large 2026 observational study of over 600,000 U.S. veterans with type 2 diabetes found that GLP-1s were associated with lower risk of developing substance use disorders involving alcohol, cannabis, cocaine, nicotine, or opioids . Among those with preexisting substance use disorders, GLP-1s were linked to lower risks of emergency room visits, hospitalizations, mortality, overdose, and suicidal thoughts or attempts.

More compelling is randomized evidence in alcohol use disorder. A small Phase 2 trial of 48 adults with alcohol use disorder found that once-weekly semaglutide reduced drinking and cravings over nine weeks compared with placebo . A recent systematic review identified 33 registered trials looking at GLP-1s for substance use disorders, predominantly for alcohol and nicotine, but with growing interest in opioid and stimulant use disorders.

What Are the Real Risks of GLP-1 Treatment?

Before considering GLP-1 drugs for pain or addiction, it's crucial to understand the potential downsides. Common side effects include nausea, vomiting, diarrhea, constipation, and appetite suppression. While often manageable, these side effects can be therapy-ending, which matters because many GLP-1 benefits appear to fade when treatment stops .

In pain and addiction care, treatment interruptions are common when insurance coverage shifts or supply is disrupted, and these interruptions can be risky. A 2026 Washington University School of Medicine analysis of veterans with type 2 diabetes found that even brief interruptions of GLP-1 treatment, as little as six months, were associated with higher risk of heart attack, stroke, and death compared with continuous use . The risks rise even further the longer the gap, with up to 22% higher risk of a major cardiovascular event after two years off therapy.

More concerning are rare but serious complications. Reports of severe delayed gastric emptying, which is stomach paralysis, remain a clinical concern. Cohort studies have also reported an association between semaglutide and neuropathy in patients with diabetes, although causality remains debated and the absolute risks are low. Emerging observational data have raised questions about musculoskeletal safety, with special relevance for people already limited by pain. Some analyses link GLP-1 use to modest reductions in bone mineral density and possible increases in osteoporosis or fracture risk in older adults. Tendon injuries have also appeared in some patients with obesity .

Steps to Take If You're Considering GLP-1 Therapy for Pain or Addiction

• Discuss with Your Doctor: Talk to your healthcare provider about whether GLP-1 drugs might be appropriate for your specific condition, weighing both potential benefits and risks based on your medical history.
• Understand Treatment Continuity: If you start GLP-1 therapy, plan for consistent, uninterrupted treatment, as stopping and starting can increase cardiovascular risks and reduce effectiveness.
• Monitor for Side Effects: Be aware of common side effects like nausea and vomiting, and report any unusual symptoms, particularly severe stomach pain or signs of nerve damage, to your healthcare provider immediately.
• Plan for Procedures: If you need surgery or a medical procedure, inform your doctor that you're taking a GLP-1 drug, as the American Society of Anesthesiologists recommends individualized perioperative strategies, including temporary liquid diets for some higher-risk patients.

Dr. Lynn Webster, Senior Fellow at the Center for U.S. Policy, emphasized the importance of evidence-based caution:

"If GLP-1s are going to move from metabolic medicine into the worlds of pain and substance use disorders, we should talk about them the way we would talk about any powerful new class: with evidence, not mythology," stated Dr. Webster.

Dr. Lynn Webster, Senior Fellow at the Center for U.S. Policy

What Comes Next for GLP-1 Research in Pain and Addiction?

The path forward requires larger, dedicated randomized trials in addiction, targeted studies in pain syndromes beyond knee osteoarthritis, longer-term musculoskeletal safety data, and honest communication about both the promise and the risks of GLP-1s . While GLP-1 drugs may end up helping people with pain and addiction, moving from "promising" to "proven" requires rigorous research and careful monitoring.

The bottom line: GLP-1 drugs are not a modern-day panacea, despite the growing hype. They show real potential for specific conditions, particularly knee osteoarthritis and alcohol use disorder, but they come with real risks that require careful consideration. Anyone interested in exploring GLP-1 therapy for chronic pain or addiction should have an informed conversation with their healthcare provider about whether the potential benefits outweigh the risks in their individual situation.